Explore the latest advances in RSV vaccine research, and what these developments mean for prevention and public health.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

Merck , known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIAtm (clesrovimab) for the prevention of respiratory syncytial virus ...

Eradivir Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today ...

The average human has about 1.8 trillion immune cells. These cells patrol the body for bacteria, viruses, cancers, and other ...

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...

AI predicted that a forgotten breast cancer drug could be repurposed to treat many respiratory and gastrointestinal viruses, and subsequent animal tests suggests it may be right ...

Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology. “We are very ...

In 2022, the team at Cortical Labs taught 800,000 brain cells in a petri dish connected to a computer how to play the 1970s game Pong. Now, years later, the same team is leveling up as they claim ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. In 2022 ...

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and ...